RLMD
NASDAQ · Pharmaceuticals
Relmada Therapeutics Inc
$6.66
+0.56 (+9.18%)
Open$6.19
Previous Close$6.10
Day High$6.74
Day Low$6.19
52W High$7.51
52W Low$0.24
Volume—
Avg Volume5.76M
Market Cap458.34M
P/E Ratio—
EPS$-1.80
SectorPharmaceuticals
Analyst Ratings
Strong Buy
9 analysts
Price Target
+461.1% upside
Current
$6.66
$6.66
Target
$37.37
$37.37
$22.23
$37.37 avg
$43.38
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 81.98M | 84.82M | 68.85M |
| Net Income | 12.35M | 12.13M | 11.14M |
| Profit Margin | 15.1% | 14.3% | 16.2% |
| EBITDA | 16.29M | 17.92M | 12.74M |
| Free Cash Flow | 15.25M | 10.32M | 8.64M |
| Rev Growth | +24.2% | +0.2% | +22.0% |
| Debt/Equity | 0.79 | 0.99 | 1.00 |
Pharmaceuticals Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Co. | $916.31 | +1.47% | 46.4 | 957.52B |
| JNJ | Johnson & Johnson | $239.93 | +1.98% | 22.2 | 594.00B |
| MRK | Merck & Co. Inc. | $119.37 | +2.58% | 16.5 | 301.17B |
| PFE | Pfizer Inc. | $27.28 | +1.19% | 19.7 | 153.36B |
| BMY | Bristol-Myers Squibb Co | $58.94 | +2.70% | 16.5 | 116.58B |
| ZTS | Zoetis Inc | $116.71 | +0.67% | 21.5 | 57.37B |